Home/Markets/KPRX
Kiora Pharmaceuticals, Inc.

KPRX

Healthcare

Kiora Pharmaceuticals, Inc.

Biotechnology

$2.51Prev. Close
$2.51
+0.00 (+0.00%)Pre-Market
For informational use only
$2.51+0.00%
Feb 6Feb 10Feb 12Feb 17Feb 19Feb 23Feb 26Mar 2Mar 4Mar 6Mar 10Mar 12Mar 16Mar 18Mar 23Mar 26Mar 31Apr 2Apr 7Apr 9Apr 13Apr 15Apr 17Apr 21Apr 23Apr 27Apr 29May 1May 6$2$2$2$3
Key events (≥5% daily moves)
Up dayDown day
About This Company

Kiora Pharmaceuticals is a healthcare company focused on developing new treatments for various eye diseases. They are working on several potential medicines, including KIO-301, which aims to restore vision for people with certain degenerative eye conditions. Other products in development are designed to treat eye inflammation and help with corneal wound repair after surgery. Since their products are still in clinical trials, they are not yet available to patients.

https://www.kiorapharma.com
Key Statistics
Open$2.49
Day High$2.57
Day Low$2.44
Prev. Close$2.51
$4.18
$1.77
$9.92M
25.29K
—
—
—
-0.47
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
12
Country
US
IPO Date
2015-02-13
Exchange
NASDAQ
$1.77
52W Low
$2.51
Current
$4.18
52W High
Catalysts & Risks
Catalysts
  • ▲Successful clinical trial results and regulatory approval for KIO-301 in retinitis pigmentosa, leading to market entry.
  • ▲Positive data and subsequent regulatory approval for KIO-101 in treating ocular surface diseases, expanding its therapeutic pipeline.
  • ▲Strategic partnerships or licensing agreements with larger pharmaceutical companies to fund development or commercialize its drug candidates.
  • ▲Expansion into new indications or successful development of additional pipeline assets, diversifying its product portfolio.
Risks
  • ▼Failure of lead product candidates (KIO-301, KIO-101) in clinical trials or inability to secure regulatory approval.
  • ▼Significant competition from larger pharmaceutical companies with more advanced or effective treatments in its target therapeutic areas.
  • ▼Inability to secure additional funding or maintain sufficient cash flow to support ongoing research and development activities.
  • ▼Intellectual property challenges, including patent disputes or the inability to adequately protect its proprietary technologies.

AI-generated · For informational use only

Own this stock?

Add it to your portfolio to track your performance.